| $385M | ||
| $350M | ||
| $215M | ||
| $94M | ||
| $82M | ||
| $62M |
Buys | $ | – | |
Sells | $ | – |
HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company is headquartered in Boston, Massachusetts.
Over the last 12 months, insiders at HilleVax, Inc. have bought $undefined and sold $undefined worth of HilleVax, Inc. stock.
On average, over the past 5 years, insiders at HilleVax, Inc. have bought $15.07M and sold $329.33M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 8,850 shares for transaction amount of $128,325 was made by Frazier Life Sciences X, L.P. (10 percent owner) on 2024‑04‑04.
| Increased Positions | 0 | 0% | 0 | 0% |
| Decreased Positions | 0 | 0% | 0 | 0% |
| New Positions | 0 | New | 0 | New |
| Sold Out Positions | 0 | Sold Out | 0 | Sold Out |
| Total Postitions | 0 | 0% | 0 | 0% |